Topotecan (HCl)

Drug #1080

Topotecan (HCl) is intravenous antineoplastic (anticancer) agent. Topotecan, similar to irinotecan, is a derivative of camptothecin (CPT), a cytotoxic plant alkaloid isolated from the Chinese tree Camptotheca acuminata. it, along with irinotecan, is the first of a new class of antineoplastics, the topoisomerse I inhibitors. Topotecan is a second-line treatment for ovarian carcinoma. It has also been investigated for treatment of non-small-cell lung carcinoma, and for chronic myelomonocytic leukemia (CMML). As a single agent, topotecan offers equal response rates to other antineoplastics for lung or ovarian carcinomas. its role in combination therapy has not yet been well defined. Topotecan was FDA approved May 29, 1996 for the treatment of metastatic ovarian carcinoma.

← Previous drug Next drug →

Primary Characteristics

It is of Semi synthetic origin and belongs to Alkaloid.

It is classified in Antineoplastic Agent, Plant Derivative pharmacological group.

Molecular Weight: 457.9 · Solubility in Water: soluble · Solubility in Alcohol: null · Non-proprietary name: Topotecan (HCl).

Pharmacokinetics

Absorption: Topotecan (HCl) has an oral bioavailability is 32% (±12%).

Distribution: Topotecan (HCl) has a volume of distribution is 74(53-95)l/m². plasma protein binding is 35 %.

Elimination: plasma half-life is 3 hr, renal excretion is 30 %.

Indications

Topotecan (HCl) is primarily indicated in conditions like Ovarian cancer, Small cell lung cancer.

Topotecan (HCl) is also indicated for secondary conditions like Metastatic ovarian cancer.

Contraindications

Topotecan (HCl) is contraindicated in conditions like Bone marrow depression.

Dosage

Topotecan (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1.5 mg/sq.meter	1.5 mg/sq.meter	Every 24h	IV Inf	Initially for 5 Days
1.5 mg/sq.meter	1.5 mg/sq.meter	Every 24h	IV Inf	Maintenance for 21-Day Course
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended in this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

None recorded.

Side Effects

Topotecan (HCl) in overdosage may give rise to further complications which include Hyperbilirubinemia, Thrombocytopenia .

Topotecan (HCl) is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Fatigue, GI disturbance, Malaise.

Warnings / Precautions

Topotecan is not recommended for use during pregnancy or lactation. Immunosuppressent drug should not be given, where possible, to patients with acute infection, dosage reduction or withdrawal should be considered if infection develops, until the infection has been controlled. Blood counts and measurement of hemoglobin concentration should be carried out routinely, help to predict the onset of bone marrow depression. It must be handled with great care and avoid contact with skin and eyes, and should not be inhaled. Avoid use in patient with impaired kidney or liver function.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

4 mg

Storage Conditions

Topotecan (HCl) should be stored Inj.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Topotecan (HCl) in Pakistan:

Atco GSK ONCOGENE